Eurofins Expands Its Leadership in Biopharmaceutical Services with the Acquisition of Advinus Therapeutics
July 26 2017 - 01:30AM
Business Wire
Regulatory News:
Eurofins Scientific (Paris:ERF) (EUFI.PA), a global leader in
bio-pharmaceutical product testing services, announces that it has
signed an exclusive agreement with Tata Group to acquire Advinus
Therapeutics (“Advinus”), a leading preclinical and clinical phase
contract research company for Safety Assessment, DMPK, CMC
services, and Analytical R&D Services. The transaction is
expected to close in the next few weeks, subject to the fulfilment
of customary closing conditions.
With over 25 years of GLP compliance and certification, Advinus
serves diverse industries such as Biotech, Pharmaceuticals,
Biologics, Agrochemicals, Nutraceuticals and Cosmetics. Advinus has
submitted over 50 end-to-end investigational new drug applications
(INDs) to global regulators such as the US Food and Drug
Administration (FDA), the European Medicines Agency (EMA), the
Medicines and Healthcare products Regulatory Agency in the UK
(MHRA) and Health Canada among others. Located in Bangalore, India,
the company operates a state-of-the art 20,000 m2 facility on a
large campus with ample space for expansion. The company generated
revenues of EUR 17m in the Fiscal Year ending 31 March 2017 with
over 300 staff.
Advinus’ expertise complements Eurofins recent contract
research, development and manufacturing (CDMO) capabilities
following the acquisitions of Alphora in Canada and Amatsigroup in
Europe. The company provides GMP testing and manufacturing
capabilities, and is well positioned to capitalize on the growing
R&D outsourcing market in the Asia-Pacific region.
Comment from Mr. KRS Jamwal, Chairman of Advinus and
Executive Director of Tata Industries: “Advinus has developed
significant promise under Tata parenting, and will now realise its
full potential joining the Eurofins family of laboratories. We are
confident that with access to Eurofins’ global network and
technical competencies, Advinus will be able to rapidly expand its
analytical portfolio and services to benefit all its existing and
future clients.”
Comment from Dr. Gilles Martin, Eurofins CEO: “We are
pleased to welcome Advinus Therapeutics to the Eurofins Group.
Advinus’ competencies and footprint further strengthen Eurofins’
global leadership in the rapidly-growing biopharmaceutical testing
market. We are committed to supporting Advinus’ further development
by providing access to the full range of services and capabilities
of the Group to the company and its clients.”
For more information, please visit
www.eurofins.com
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter
sometimes “Eurofins” or “the Group”) believes it is the world
leader in food, environment and pharmaceutical products testing and
that it is also one of the global independent market leaders in
certain testing and laboratory services for agroscience, genomics,
discovery pharmacology and for supporting clinical studies. In
addition, Eurofins is one of the key emerging players in specialty
clinical diagnostic testing in Europe and the USA. With over 30,000
staff in 375 laboratories across 41 countries, Eurofins offers a
portfolio of over 130,000 analytical methods for evaluating the
safety, identity, composition, authenticity, origin and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group objective is to provide its
customers with high-quality services, accurate results on time and
expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170725006043/en/
Investor RelationsEurofins ScientificPhone: +32 2 766
1620E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Feb 2024 to Mar 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Mar 2023 to Mar 2024